London University To Begin Magic Mushroom Based Clinical Trial
Ever since hallucinogens such as LSD were banned back in the 1960’s, the research surrounding their potential medical value ground to a halt. It didn’t matter that positive results were already being found, science was officially prohibited from exploring the matter further.
This stance on hallucinogenic based research has changed over the last year or so, with rational science and reasoning overcoming the ban. We recently reported how a UK based scientist was conducting initial forays into this field of science, to revitalise it and assess how hallucinogens interact with the brain. Well, this is all being taken one step further, as a the Imperial College London plans to conduct actual and legitimate clinical human trials this April into the depression relieving effects of psilocybin – the active compound of magic mushrooms.
IT’S HUGELY SIGNIFICANT
This is the first UK based clinical trial to be conducted with hallucinogens in over 45 years, making it is an extremely significant step forward for this field of science. Other research has been conducted, but these have been initial small sample studies, conducted to determine whether there is actual grounds for clinical trial.
It is hoped that through this trial that the impact of hallucinogens on anxiety and depression can be better understood, and any real potential for medical application become better realised. The university predicts a positive outcome, especially for those suffering from, but struggling to deal with terminal illnesses, such as cancer.
Recent studies from the US are already showing that even a single dose as part of therapy can be hugely beneficial to those suffering from anxiety, depression and addiction, so we are very eager to see how clinical trials go on this side of the pond. If it is successful, we will have taken the next step in bringing hallucinogens into modern medicine.